

# General Schedule

---



## EU-MIND

European Meeting on Imaging  
of Neurodegenerative Diseases

2<sup>nd</sup> EDITION > BARCELONA, SPAIN 2026

# prePROGRAM

Founders



## Plenary Sessions

### What's new? - by **Anna Dewenter**



She is a Postdoctoral Researcher at the Institute for Stroke and Dementia Research (ISD), LMU Munich, Germany. She holds a Bachelor's in Cognitive Science from the University of Osnabrück (with a semester at University of York, UK) and a Research Master's in Cognitive Neuroscience from the Donders Institute, Nijmegen, Netherlands. She earned her PhD in Systemic Neurosciences at LMU Munich, studying structural connectivity changes in cerebral small vessel disease (SVD) and Alzheimer's disease (AD), including a research visit at Massachusetts General Hospital, Boston. Her work focuses on sensitive biomarkers for SVD/AD and mechanisms linking cerebrovascular and neurodegenerative diseases.

### Neuroimaging meets AI - by **Helen Zhou**



She is an Associate Professor and Director of the Centre for Translational MR Research at the Yong Loo Lin School of Medicine, NUS. Her work focuses on brain network vulnerability in aging and neuropsychiatric disorders using multimodal neuroimaging and machine learning. A pioneer in the brain connectome field, she now advances brain foundation models with deep learning. Trained at NTU and UCSF, she also worked with MIT and NYU. An OHBM Fellow and editor for major journals, her research is supported by agencies in Singapore, the UK, and the US.

### CAA: imaging and small vessel pathology – by **Susanne van Veluw**



She is Professor of Translational Vascular Neuroscience at the University of Edinburgh, UK. She earned her PhD in Clinical Neuroscience at Utrecht University Medical Centre, Netherlands, followed by postdoctoral training at Massachusetts General Hospital and Harvard Medical School in Boston. There, she founded the Translational CAA Research Lab to study microvascular brain injury in cerebral amyloid angiopathy (CAA), linked to haemorrhagic stroke and cognitive decline. The lab uses in vivo MRI, ex vivo histopathology, and two-photon microscopy to identify treatment targets. In summer 2025, it relocated to the UK's BHF-UK DRI Centre for Vascular Dementia Research.

# Scientific Content

---

## Symposia topics and confirmed speakers

### **The role of sleep in NDD**

with Géraldine Rauchs  
and Anders Fjell

### **AI & ML**

with James Cole

### **Interventions**

with Nick Fox  
and Antonio Valero-Cabré

### **Imaging Methods**

with Nikolaus Weiskopf  
and Beatriz Padrela

### **Non-AD / polypathology**

with Rosaleena Mohanty  
and Bàrbara Segura

### **Omics & Connectomics**

with Mario Tranfa  
and Alessandra Griffo

*\* additional talks will be added in each symposia based on the best received communications*

# General Schedule

Morning

Plenary #2

Plenary #3

Symposia\*

Symposia\*

Datablitz

Closing remarks

Plenary #1

Symposia\*

+ poster session

Symposia\*

Symposia\*

Datablitz

Symposia\*

Social Activity

Welcome Reception

Afternoon

*\* additional talks will be added in each symposia based on the best received communications*